| 1. |
秦洁莉. 白蛋白结合型紫杉醇的作用机制和其给药系统的研究进展[J]. 北方药学, 2014(9): 71-74.Qin JL. Research progress on the mechanism of action and drug delivery system of albumin-bound paclitaxel[J]. Journal of North Pharmacy, 2014(9): 71-74.
|
| 2. |
Hofstra L, de Vries E, Willemse P. Ophthalmic toxicity following paclitaxel infusion[J]. Ann Oncol, 1997, 8(10): 1053. DOI: 10.1023/a:1008249230056.
|
| 3. |
Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders[J]. Drug Saf, 2008, 31(2): 127-141. DOI: 10.2165/00002018-200831020-00003.
|
| 4. |
Álvarez-Fernández D, Cubillas-Martín M, Álvarez-Suárez ML, et al. Macular oedema associated with taxanes: a case report and literature review[J]. Arch Soc Esp Oftalmol (Engl Ed), 2020, 95(10): 485-495. DOI: 10.1016/j.oftal.2020.05.030.
|
| 5. |
Nomi N, Ota M, Fukumura M, et al. Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy[J]. Jpn J Ophthalmol, 2018, 62(2): 163-167. DOI: 10.1007/s10384-017-0552-7.
|
| 6. |
Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy[J]. Arch Ophthalmol, 2008, 126(11): 1605-1606. DOI: 10.1001/archopht.126.11.1605.
|
| 7. |
Shih CH, Lee YC. Impaired retinal pigment epithelium in paclitaxel-induced macular edema[J/OL]. Medicine (Baltimore), 2018, 97(26): e11229[2018-06-01]. https://pubmed.ncbi.nlm.nih.gov/29952984/. DOI: 10.1097/MD.0000000000011229.
|
| 8. |
Chelala E, Arej N, Antoun J, et al. Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients[J]. Chemotherapy, 2017, 62(3): 199-204. DOI: 10.1159/000456653.
|
| 9. |
Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes[J]. Int Ophthalmol, 2012, 32(3): 299-304. DOI: 10.1007/s10792-012-9558-9.
|
| 10. |
Freitas-da-Costa P, Brandão E, Bragança T, et al. Multimodal imaging in paclitaxel-induced macular edema: the microtubule disfunction[J]. Cutan Ocul Toxicol, 2015, 34(4): 347-349. DOI: 10.3109/15569527.2014.996294.
|
| 11. |
Sridhar J, Shahlaee A, Ehmann D, et al. En face optical coherence tomography and optical coherence tomography angiography imaging of taxane-associated cystoid macular edema[J]. Ophthalmic Surg Lasers Imaging Retina, 2016, 47(2): 176-179. DOI: 10.3928/23258160-20160126-12.
|
| 12. |
Joshi MM. Paclitaxel maculopathy[J]. Arch Ophthalmol, 2007, 125(5): 709. DOI: 10.1001/archopht.125.5.709.
|
| 13. |
Ehlers JP, Rayess H, Steinle N. Topical dorzolamide therapy for taxane-related macular oedema[J]. Eye (Lond), 2013, 27(1): 102-104. DOI: 10.1038/eye.2012.228.
|
| 14. |
Dwivedi R, Tiroumal S. Possible efficacy of topical dorzolamide in the treatment of paclitaxel-related cystoid macular edema[J]. Retin Cases Brief Rep, 2018, 12(1): 75-79. DOI: 10.1097/ICB.0000000000000433.
|
| 15. |
Meyer KM, Klink T, Ugurel S, et al. Regression of paclitaxel-induced maculopathy with oral acetazolamide[J]. Graefe's Arch Clin Exp Ophthalmol, 2012, 250(3): 463-464. DOI: 10.1007/s00417-011-1642-8.
|
| 16. |
Matsuoka N, Hasebe H, Mayama T, et al. Sub-tenon injections of triamcinolone acetonide had limited effect on cystoid macular edema econdary to albumin-bound-paclitaxel (Abraxane)[J/OL]. Case Rep Ophthalmol Med, 2015: 181269[2015-08-23]. https://pubmed.ncbi.nlm.nih.gov/26366312/. DOI: 10.1155/2015/181269.
|
| 17. |
Burgos-Blasco B, Hernandez-Ruiz S, Lopez-Guajardo L, et al. Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy[J/OL]. Am J Ophthalmol Case Rep, 2020, 18: 100653[2020-03-07]. https://pubmed.ncbi.nlm.nih.gov/32190783/. DOI: 10.1016/j.ajoc.2020.100653.
|
| 18. |
Hassall MM, Andrew NH. Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema[J/OL]. BMJ Case Rep, 2016, 19: bcr2015212733[2016-04-19]. https://pubmed.ncbi.nlm.nih.gov/27095804/. DOI: 10.1136/bcr-2015-212733.
|
